Company intelligence / Profile preview

Bioarray Genetics

Farmington, Connecticut, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Bioarray Genetics develops in-vitro diagnostic tests that analyze a patient’s gene expression profile to predict response to chemotherapy, specifically for breast cancer. Their lead test, BA100, identifies non-responders to standard-of-care chemotherapy, aiming to reduce ineffective treatments and improve patient outcomes. Clinical outcomes data suggest BA100 can reduce ineffective chemotherapy by 55% and increase treatment response by 68% compared to standard treatment. There is no evidence of therapeutic drug development in the pipeline.

Therapeutic areas: Oncology
Modalities: RNA-based predictive testIn-vitro diagnostic testCompanion diagnostic
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Bioarray Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioarray Genetics.

Explore the full profile